Espero Pharmaceuticals Receives FDA Approval for GONITRO™ (Nitroglycerin) Sublingual Powder

JACKSONVILLE, Fla. (June 14, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. With this approval, GONITRO™ is the first and […]

Read more

Espero Pharmaceuticals Announces Promotion of Nitrolingual® Pumpspray (nitroglycerin lingual spray)

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today assumed the U.S. promotional responsibility for Nitrolingual® Pumpspray, in an exclusive licensing agreement with G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”), a fully-integrated German pharmaceutical company. Jacksonville Pharmaceuticals, a wholly owned subsidiary of Espero Pharmaceuticals, has also assumed distribution and supply responsibility […]

Read more

Espero Pharmaceuticals Announces Board and Executive Appointments

• Former CEO of Novartis and Astra-Merck Wayne Yetter joins Board • Co-founder Jeff Cole appointed President, CFO and Director • Sean Purdy hired as VP of Commercial Operations JACKSONVILLE, FL, February 17, 2016 – Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the appointment of industry veteran Wayne Yetter as […]

Read more

Espero Pharmaceuticals to Present at Biotech Showcase 2016

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced its participation in the 8th Annual Biotech ShowcaseTM Conference in San Francisco, CA on January 11-13, 2016. Mr. Quang Pham, Founder and CEO, will discuss recent Company developments in his presentation on Tuesday, January 12 at 2:45pm PST at the Parc […]

Read more

Espero Pharmaceuticals Announces FDA Acceptance of New Drug Application for GoNitro™ (Nitroglycerin Powder for Sublingual Use)

JACKSONVILLE, FL–(BUSINESS WIRE)–Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for GoNitro™ for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. “The FDA’s acceptance for review of […]

Read more

Espero Pharmaceuticals Announces Exclusive Licensing and Distribution Agreement

JACKSONVILLE, FL–(BUSINESS WIRE)–Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the signing of an exclusive Licensing and Distribution Agreement with G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”), a fully-integrated German pharmaceutical company with a 175 year operating history, for its new nitroglycerin sublingual powder formulation for acute relief of an attack […]

Read more

Espero Pharmaceuticals Closes Seed Funding Round

JACKSONVILLE, FL – Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the closing of a private round of funding as well as an equity investment made by G. Pohl-Boskamp GmbH & Co. KG (Pohl-Boskamp), a fully-integrated German pharmaceutical company with a 175 year operating history. Espero will use the proceeds to […]

Read more

1 2